IDSI also has accepted the resignations of three outside directors -- Jay Bendis, Patrick Gorman, and Sherman Lazrus -- as a condition to receive funding from an outside source.
On April 18, IDSI entered into an agreement with investment firm Charlton Avenue for a maximum commitment of $15 million for three years from the effective date of the resignations.
The company currently is conducting clinical studies for a premarket approval (PMA) application to the U.S. Food and Drug Administration for its computed tomography laser mammography (CTLM) system. The technology is limited to investigational use only in the U.S.
IDSI says Hansen to retire as CEO, December 28, 2007
IDSI adds CTLM trial site, November 29, 2007
IDSI sells HQ for $4.4 million in leaseback deal, September 19, 2007
IDSI sends CTLM unit to Malaysia, September 5, 2007
Study: IDS' CTLM aids in dense-breast imaging, June 26, 2007
Copyright © 2008 AuntMinnie.com